Heghine Khachatryan: New Evidence in Secondary Stroke Prevention: Cilostazol + Aspirin vs Ticagrelor + Aspirin
Heghine Khachatryan, Editor-in-Chief of Hemostasis Today, Head of Hemophilia and Thrombosis Center at Yeolyan Hematology and Oncology Center, shared a post by International Journal of Stroke on LinkedIn:
“New evidence in secondary stroke prevention
A recent study published in the International Journal of Stroke reports that cilostazol plus aspirin significantly reduces recurrent stroke, myocardial infarction, and vascular death, with comparable efficacy to ticagrelor plus aspirin in the acute-phase treatment of large-vessel disease.
Why this matters
• Provides an alternative dual antiplatelet strategy with proven effectiveness
• Particularly relevant for patients with high bleeding risk, intolerance, or contraindications to potent P2Y12 inhibitors
• Highlights the growing role of cilostazol-based regimens beyond East Asian populations
-This study adds valuable data to ongoing discussions on individualized antiplatelet therapy after ischemic stroke and reinforces the need to balance efficacy with safety.
Full article: Ticagrelor plus aspirin versus cilostazol plus aspirin in the acute-phase treatment of large-vessel disease”
Quoting International Journal of Stroke‘s post:
“Study finds cilostazol plus aspirin reduced recurrent stroke, MI, and vascular death with a comparable rate to ticagrelor plus aspirin
However, cilostazol plus aspirin showed significantly lower rates of hemorrhagic complications and better tolerability
Read more here.”
Title: Ticagrelor plus aspirin versus cilostazol plus aspirin in the acute-phase treatment of large-vessel minor stroke or TIA: A randomized controlled multi-center trial, the TACTIS trial
Authors: Mohamed Ismaiel, Sherihan Rezk ahmed et al.
Stay updated and find more posts featuring Heghine Khachatryan on Hemostasis Today.
-
Jun 2, 2026, 15:28Kabilan K. L.: Management and Diagnosis of Acute Coronary Syndrome Types
-
Jun 2, 2026, 15:26Mital Jhaveri: What New Data Reveal About DOACs and Androgen Receptor Inhibitors?
-
Jun 2, 2026, 15:22Dhananjaya Kotebagilu Narayana Vamyanmane: High-Resolution Ultrasound Evaluation of Bowel Wall Ischemia
-
Jun 2, 2026, 15:20Joep Schellens: Influence of Dexamethasone and Tocilizumab on Fibrinolysis in COVID-19
-
Jun 2, 2026, 15:12Ebrahim Umer: The Sickest Liver Patients Deserve One Language – Lessons from the Kyoto Consensus
-
Jun 2, 2026, 15:10Ney Carter Borges: Bempedoic Acid and Venous Thromboembolism Risk in Statin-Intolerant Patients
-
Jun 2, 2026, 15:07Sayan Koley: Coagulation Science – Where Precision Saves Lives
-
Jun 2, 2026, 15:04Ahmed Mohsen: Low CHA₂DS₂-VA Score Does Not Always Mean No Anticoagulation
-
Jun 2, 2026, 15:04The Risk Factors and Optimal Prevention Strategies of VTE in Sickle Cell Disease – RPTH Journal